Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 3/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 6/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870601 | 0.77 | SSTR4 (0.41) | SSTR4REN | |
| SCHEMBL2535111 | 0.73 | CPN1 (0.40) | CPN1CPB2SSTR4 | |
| SCHEMBL294389 | 0.71 | REN (0.41) | SSTR4REN | |
| SCHEMBL9208253 | 0.70 | MMP2 (0.50) | CPN1CPB2LTA4HMMP2MMP9 | |
| SCHEMBL2856572 | 0.70 | MMP2 (0.50) | CPN1CPB2LTA4HMMP2MMP9 | |
| SCHEMBL31109109 | 0.70 | LTA4H (0.48) | CPN1CPB2LTA4HMMP2MMP9 | |
| SCHEMBL8871986 | 0.70 | CPN1 (0.50) | CPN1CPB2LTA4HMMP2MMP9 | |
| SCHEMBL2926325 | 0.69 | SSTR4 (0.56) | SSTR4MMP2MMP9 | |
| SCHEMBL4603755 | 0.69 | MMP2 (0.51) | CPN1CPB2LTA4HMMP2MMP9 | |
| SCHEMBL4603751 | 0.69 | MMP2 (0.51) | CPN1CPB2LTA4HMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CPN1 1/4885CPB2 9/4885SSTR4 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.